vs

Side-by-side financial comparison of Emerson Electric (EMR) and IQVIA (IQV). Click either name above to swap in a different company.

Emerson Electric is the larger business by last-quarter revenue ($4.6B vs $4.2B, roughly 1.1× IQVIA). Emerson Electric runs the higher net margin — 13.5% vs 6.6%, a 6.9% gap on every dollar of revenue. On growth, IQVIA posted the faster year-over-year revenue change (8.4% vs 3.0%). Emerson Electric produced more free cash flow last quarter ($694.0M vs $491.0M). Over the past eight quarters, IQVIA's revenue compounded faster (4.3% CAGR vs -0.6%).

Emerson Electric Co. is an American multinational corporation headquartered in St. Louis, Missouri. The Fortune 500 company delivers a range of engineering services, manufactures industrial automation equipment, climate control systems, and precision measurement instruments, and provides software engineering for industrial, commercial, and consumer markets.

IQVIA Holdings, Inc., headquartered in Durham, North Carolina, is an American company focused on health information technology and clinical research.

EMR vs IQV — Head-to-Head

Bigger by revenue
EMR
EMR
1.1× larger
EMR
$4.6B
$4.2B
IQV
Growing faster (revenue YoY)
IQV
IQV
+5.4% gap
IQV
8.4%
3.0%
EMR
Higher net margin
EMR
EMR
6.9% more per $
EMR
13.5%
6.6%
IQV
More free cash flow
EMR
EMR
$203.0M more FCF
EMR
$694.0M
$491.0M
IQV
Faster 2-yr revenue CAGR
IQV
IQV
Annualised
IQV
4.3%
-0.6%
EMR

Income Statement — Q3 FY2026 vs Q1 FY2026

Metric
EMR
EMR
IQV
IQV
Revenue
$4.6B
$4.2B
Net Profit
$618.0M
$275.0M
Gross Margin
53.1%
Operating Margin
12.4%
Net Margin
13.5%
6.6%
Revenue YoY
3.0%
8.4%
Net Profit YoY
43.7%
10.0%
EPS (diluted)
$1.10
$1.61

Green = leading value per metric. Periods may differ when fiscal calendars don't align.

8-Quarter Revenue & Profit Trend

Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.

Revenue
EMR
EMR
IQV
IQV
Q2 26
$4.6B
Q1 26
$4.3B
$4.2B
Q4 25
$4.3B
$4.4B
Q3 25
$4.9B
$4.1B
Q2 25
$4.6B
$4.0B
Q1 25
$4.4B
$3.8B
Q4 24
$4.2B
$4.0B
Q3 24
$4.6B
$3.9B
Net Profit
EMR
EMR
IQV
IQV
Q2 26
$618.0M
Q1 26
$606.0M
$275.0M
Q4 25
$605.0M
$514.0M
Q3 25
$637.0M
$331.0M
Q2 25
$586.0M
$266.0M
Q1 25
$485.0M
$249.0M
Q4 24
$585.0M
$437.0M
Q3 24
$996.0M
$285.0M
Gross Margin
EMR
EMR
IQV
IQV
Q2 26
53.1%
Q1 26
53.2%
Q4 25
53.2%
Q3 25
51.9%
Q2 25
52.6%
Q1 25
53.5%
Q4 24
53.5%
Q3 24
51.3%
23.5%
Operating Margin
EMR
EMR
IQV
IQV
Q2 26
Q1 26
12.4%
Q4 25
17.8%
14.4%
Q3 25
16.4%
13.5%
Q2 25
16.1%
12.6%
Q1 25
14.2%
13.0%
Q4 24
18.6%
15.8%
Q3 24
14.7%
14.1%
Net Margin
EMR
EMR
IQV
IQV
Q2 26
13.5%
Q1 26
13.9%
6.6%
Q4 25
13.9%
11.8%
Q3 25
13.1%
8.1%
Q2 25
12.9%
6.6%
Q1 25
10.9%
6.5%
Q4 24
14.0%
11.0%
Q3 24
21.6%
7.3%
EPS (diluted)
EMR
EMR
IQV
IQV
Q2 26
$1.10
Q1 26
$1.07
$1.61
Q4 25
$1.07
$2.97
Q3 25
$1.12
$1.93
Q2 25
$1.04
$1.54
Q1 25
$0.86
$1.40
Q4 24
$1.02
$2.41
Q3 24
$1.74
$1.55

Balance Sheet & Financial Strength

Snapshot of each company's liquidity, leverage and book value from the latest quarter.

Metric
EMR
EMR
IQV
IQV
Cash + ST InvestmentsLiquidity on hand
$1.8B
$1.9B
Total DebtLower is stronger
$13.4B
$15.8B
Stockholders' EquityBook value
$20.3B
$6.3B
Total Assets
$42.1B
$29.7B
Debt / EquityLower = less leverage
0.66×
2.49×

8-quarter trend — quarters aligned by calendar period.

Cash + ST Investments
EMR
EMR
IQV
IQV
Q2 26
$1.8B
Q1 26
$1.7B
$1.9B
Q4 25
$2.1B
Q3 25
$2.0B
Q2 25
$2.2B
Q1 25
$1.9B
Q4 24
$1.8B
Q3 24
$1.7B
Total Debt
EMR
EMR
IQV
IQV
Q2 26
$13.4B
Q1 26
$13.4B
$15.8B
Q4 25
$7.6B
Q3 25
$8.9B
Q2 25
$8.3B
Q1 25
$8.2B
Q4 24
$6.6B
Q3 24
$7.7B
Stockholders' Equity
EMR
EMR
IQV
IQV
Q2 26
$20.3B
Q1 26
$20.3B
$6.3B
Q4 25
$20.3B
$6.5B
Q3 25
$20.3B
$6.2B
Q2 25
$19.9B
$5.8B
Q1 25
$19.2B
$6.0B
Q4 24
$20.5B
$6.1B
Q3 24
$21.6B
$7.0B
Total Assets
EMR
EMR
IQV
IQV
Q2 26
$42.1B
Q1 26
$41.9B
$29.7B
Q4 25
$41.9B
$29.9B
Q3 25
$42.0B
$28.7B
Q2 25
$42.5B
$28.6B
Q1 25
$42.0B
$27.3B
Q4 24
$42.6B
$26.9B
Q3 24
$44.2B
$27.2B
Debt / Equity
EMR
EMR
IQV
IQV
Q2 26
0.66×
Q1 26
0.66×
2.49×
Q4 25
0.37×
Q3 25
0.44×
Q2 25
0.42×
Q1 25
0.42×
Q4 24
0.32×
Q3 24
0.36×

Cash Flow & Capital Efficiency

How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.

Metric
EMR
EMR
IQV
IQV
Operating Cash FlowLast quarter
$618.0M
Free Cash FlowOCF − Capex
$694.0M
$491.0M
FCF MarginFCF / Revenue
15.2%
11.8%
Capex IntensityCapex / Revenue
4.0%
Cash ConversionOCF / Net Profit
2.25×
TTM Free Cash FlowTrailing 4 quarters
$4.6B
$2.1B

8-quarter trend — quarters aligned by calendar period.

Operating Cash Flow
EMR
EMR
IQV
IQV
Q2 26
Q1 26
$618.0M
Q4 25
$699.0M
$735.0M
Q3 25
$3.1B
$908.0M
Q2 25
$1.1B
$443.0M
Q1 25
$241.0M
$568.0M
Q4 24
$777.0M
$885.0M
Q3 24
$3.3B
$721.0M
Free Cash Flow
EMR
EMR
IQV
IQV
Q2 26
$694.0M
Q1 26
$602.0M
$491.0M
Q4 25
$602.0M
$561.0M
Q3 25
$2.7B
$772.0M
Q2 25
$977.0M
$292.0M
Q1 25
$154.0M
$426.0M
Q4 24
$694.0M
$721.0M
Q3 24
$2.9B
$571.0M
FCF Margin
EMR
EMR
IQV
IQV
Q2 26
15.2%
Q1 26
13.9%
11.8%
Q4 25
13.9%
12.9%
Q3 25
54.9%
18.8%
Q2 25
21.5%
7.3%
Q1 25
3.5%
11.1%
Q4 24
16.6%
18.2%
Q3 24
63.1%
14.7%
Capex Intensity
EMR
EMR
IQV
IQV
Q2 26
4.0%
Q1 26
2.2%
Q4 25
2.2%
4.0%
Q3 25
8.9%
3.3%
Q2 25
2.0%
3.8%
Q1 25
2.0%
3.7%
Q4 24
2.0%
4.1%
Q3 24
9.1%
3.9%
Cash Conversion
EMR
EMR
IQV
IQV
Q2 26
Q1 26
2.25×
Q4 25
1.16×
1.43×
Q3 25
4.86×
2.74×
Q2 25
1.83×
1.67×
Q1 25
0.50×
2.28×
Q4 24
1.33×
2.03×
Q3 24
3.35×
2.53×

Financial Flow Comparison

Revenue → gross profit → operating profit → net profit for each company.

Related Comparisons